Last reviewed · How we verify
narmafotinib ascending doses — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
narmafotinib ascending doses (narmafotinib ascending doses) — Amplia Therapeutics Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| narmafotinib ascending doses TARGET | narmafotinib ascending doses | Amplia Therapeutics Limited | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- narmafotinib ascending doses CI watch — RSS
- narmafotinib ascending doses CI watch — Atom
- narmafotinib ascending doses CI watch — JSON
- narmafotinib ascending doses alone — RSS
Cite this brief
Drug Landscape (2026). narmafotinib ascending doses — Competitive Intelligence Brief. https://druglandscape.com/ci/narmafotinib-ascending-doses. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing